PMID- 27260561 OWN - NLM STAT- MEDLINE DCOM- 20171010 LR - 20220316 IS - 1873-6815 (Electronic) IS - 0531-5565 (Print) IS - 0531-5565 (Linking) VI - 86 DP - 2016 Dec 15 TI - Energetic interventions for healthspan and resiliency with aging. PG - 73-83 LID - S0531-5565(16)30147-4 [pii] LID - 10.1016/j.exger.2016.05.012 [doi] AB - Several behavioral and pharmacological strategies improve longevity, which is indicative of delayed organismal aging, with the most effective interventions extending both life- and healthspan. In free living creatures, maintaining health and function into old age requires resilience against a multitude of stressors. Conversely, in experimental settings, conventional housing of rodents limits exposure to such challenges, thereby obscuring an accurate assessment of resilience. Caloric restriction (CR) and exercise, as well as pharmacologic strategies (resveratrol, rapamycin, metformin, senolytics), are well established to improve indices of health and aging, but some paradoxical effects have been observed on resilience. For instance, CR potently retards the onset of age-related diseases, and improves lifespan to a greater extent than exercise in a variety of models. However, exercise has proven more consistently beneficial to organismal resilience against a broad array of stressors, including infections, surgery, wound healing and frailty. CR can improve cellular stress defenses and protect from frailty, but also impairs the response to infections, bed rest and healing. How an intervention will impact not only longevity, health and function, but also resiliency, is critical to better understanding translational implications. Thus, organismal robustness represents a critical, albeit understudied aspect of aging, which needs more careful attention in order to better inform on how putative age-delaying strategies will impact preservation of health and function in response to stressors with aging in humans. CI - Copyright (c) 2016 Elsevier Inc. All rights reserved. FAU - Huffman, Derek M AU - Huffman DM AD - Department of Molecular Pharmacology and Medicine, Albert Einstein College of Medicine, Bronx, NY, USA; Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: derek.huffman@einstein.yu.edu. FAU - Schafer, Marissa J AU - Schafer MJ AD - Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA. FAU - LeBrasseur, Nathan K AU - LeBrasseur NK AD - Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA. LA - eng GR - P01 AG041122/AG/NIA NIH HHS/United States GR - P30 AG038072/AG/NIA NIH HHS/United States GR - P30 DK020541/DK/NIDDK NIH HHS/United States GR - R00 AG037574/AG/NIA NIH HHS/United States PT - Journal Article PT - Review DEP - 20160531 PL - England TA - Exp Gerontol JT - Experimental gerontology JID - 0047061 RN - 0 (Stilbenes) RN - 9100L32L2N (Metformin) RN - Q369O8926L (Resveratrol) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Aging/drug effects/*physiology MH - Caloric Restriction/*methods MH - *Diet MH - Energy Intake/*physiology MH - Exercise/physiology MH - Female MH - Humans MH - Longevity/*physiology MH - Male MH - Metformin/therapeutic use MH - Resveratrol MH - Sirolimus/therapeutic use MH - Stilbenes/therapeutic use PMC - PMC5133182 MID - NIHMS809124 OTO - NOTNLM OT - Aging OT - Caloric restriction OT - Diet OT - Exercise OT - Metformin OT - Rapamycin OT - Resiliency OT - Resveratrol OT - Robustness OT - Senolytics EDAT- 2016/06/05 06:00 MHDA- 2017/10/11 06:00 PMCR- 2017/12/15 CRDT- 2016/06/05 06:00 PHST- 2016/01/20 00:00 [received] PHST- 2016/05/03 00:00 [revised] PHST- 2016/05/24 00:00 [accepted] PHST- 2016/06/05 06:00 [pubmed] PHST- 2017/10/11 06:00 [medline] PHST- 2016/06/05 06:00 [entrez] PHST- 2017/12/15 00:00 [pmc-release] AID - S0531-5565(16)30147-4 [pii] AID - 10.1016/j.exger.2016.05.012 [doi] PST - ppublish SO - Exp Gerontol. 2016 Dec 15;86:73-83. doi: 10.1016/j.exger.2016.05.012. Epub 2016 May 31.